Cookie Consent by Free Privacy Policy Generator Update cookies preferences

Session 34

OESO-SEMPIRE 16th World Conference | Esophagus 2024 | Strasbourg | April 23-26, 2024 | Venue: IRCAD France

<  back to Program at a glance
<  back to all the scientific sessions


Session 34: Updates in GERD

Friday, April 26, 4:00 – 5:30 pm
Auditorium Léon Hirsch

Session II:
ChairsWalter W. Chan (USA) – Kerry B. Dunbar (USA)

  1. Chronic proton pump inhibitor use is bad for my health – myth or fact? – Lawrence F. Borges (USA)
  2. What is the efficacy of PPI for different typical reflux symptoms? – John O. Clarke (USA)
  3. How effective is acid suppression therapy for cough and pulmonary symptoms? – Walter W. Chan (USA)
  4. Does acid suppression therapy have a role in management of reflux hypersensitivity and functional heartburn? 
  5. Should on-demand acid suppression be used in treatment of reflux symptoms? – Kerry B. Dunbar (USA)
  6. What is the role of GABA agonists in the management of reflux symptoms? – Reena Chokshi (USA)
  7. When should mucosal coating agents be used in reflux management? – Rona Marie Lawenko (Philippines)
  8. How does PCAB compare to PPI in endoscopic reflux healing? – Sravanya Gavini (USA)
  9. Are PCAB better than PPI in reflux symptoms control? – Ellen M. Stein (USA)
  10. What are effective therapies for nocturnal acid breakthrough for patients on twice daily PPI? – Irene Sonu (USA)
  11. When should PCAB be considered? – Jose M. Remes-Troche (Mexico)